Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort.

Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE, Henriksen J, Darvas M, Domoto-Reilly K, Jayadev S, Grabowski TJ, Crane PK, Larson EB, Kraemer BC, Bird TD, Keene CD.

Acta Neuropathol Commun. 2019 Jun 7;7(1):91. doi: 10.1186/s40478-019-0743-1. Erratum in: Acta Neuropathol Commun. 2019 Aug 14;7(1):131.

2.

Tau tubulin kinases in proteinopathy.

Taylor LM, McMillan PJ, Kraemer BC, Liachko NF.

FEBS J. 2019 Jul;286(13):2434-2446. doi: 10.1111/febs.14866. Epub 2019 May 22. Review.

PMID:
31034749
3.

Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects.

Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, Gao J, Pandey A, Taylor JP, Kraemer BC, Wu P, Boldogh I, Garruto RM, Mitra S, Rao KS, Hegde ML.

Proc Natl Acad Sci U S A. 2019 Feb 15. pii: 201818415. doi: 10.1073/pnas.1818415116. [Epub ahead of print]

PMID:
30770445
4.

α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-43 proteinopathy.

Wong SQ, Pontifex MG, Phelan MM, Pidathala C, Kraemer BC, Barclay JW, Berry NG, O'Neill PM, Burgoyne RD, Morgan A.

Neurobiol Dis. 2018 Oct;118:40-54. doi: 10.1016/j.nbd.2018.06.013. Epub 2018 Jun 22.

5.

Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.

Taylor LM, McMillan PJ, Liachko NF, Strovas TJ, Ghetti B, Bird TD, Keene CD, Kraemer BC.

Mol Neurodegener. 2018 Feb 6;13(1):7. doi: 10.1186/s13024-018-0237-9.

6.

Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing.

Weeks JC, Roberts WM, Leasure C, Suzuki BM, Robinson KJ, Currey H, Wangchuk P, Eichenberger RM, Saxton AD, Bird TD, Kraemer BC, Loukas A, Hawdon JM, Caffrey CR, Liachko NF.

Sci Rep. 2018 Jan 17;8(1):975. doi: 10.1038/s41598-017-18457-w.

7.

DOPA Decarboxylase Modulates Tau Toxicity.

Kow RL, Sikkema C, Wheeler JM, Wilkinson CW, Kraemer BC.

Biol Psychiatry. 2018 Mar 1;83(5):438-446. doi: 10.1016/j.biopsych.2017.06.007. Epub 2017 Jun 15.

8.

TDP-43/FUS in motor neuron disease: Complexity and challenges.

Guerrero EN, Wang H, Mitra J, Hegde PM, Stowell SE, Liachko NF, Kraemer BC, Garruto RM, Rao KS, Hegde ML.

Prog Neurobiol. 2016 Oct - Nov;145-146:78-97. doi: 10.1016/j.pneurobio.2016.09.004. Epub 2016 Sep 28. Review.

9.

The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.

Liachko NF, Saxton AD, McMillan PJ, Strovas TJ, Currey HN, Taylor LM, Wheeler JM, Oblak AL, Ghetti B, Montine TJ, Keene CD, Raskind MA, Bird TD, Kraemer BC.

Acta Neuropathol. 2016 Oct;132(4):545-61. doi: 10.1007/s00401-016-1600-y. Epub 2016 Jul 29.

10.

Blast exposure causes dynamic microglial/macrophage responses and microdomains of brain microvessel dysfunction.

Huber BR, Meabon JS, Hoffer ZS, Zhang J, Hoekstra JG, Pagulayan KF, McMillan PJ, Mayer CL, Banks WA, Kraemer BC, Raskind MA, McGavern DB, Peskind ER, Cook DG.

Neuroscience. 2016 Apr 5;319:206-20. doi: 10.1016/j.neuroscience.2016.01.022. Epub 2016 Jan 14.

11.

Repetitive blast exposure in mice and combat veterans causes persistent cerebellar dysfunction.

Meabon JS, Huber BR, Cross DJ, Richards TL, Minoshima S, Pagulayan KF, Li G, Meeker KD, Kraemer BC, Petrie EC, Raskind MA, Peskind ER, Cook DG.

Sci Transl Med. 2016 Jan 13;8(321):321ra6. doi: 10.1126/scitranslmed.aaa9585.

PMID:
26764157
12.

Erratum to: Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression.

Chen X, McCue HV, Wong SQ, Kashyap SS, Kraemer BC, Barclay JW, Burgoyne RD, Morgan A.

Mol Neurodegener. 2015 Oct 23;10:54. doi: 10.1186/s13024-015-0051-6.

13.

Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression.

Chen X, McCue HV, Wong SQ, Kashyap SS, Kraemer BC, Barclay JW, Burgoyne RD, Morgan A.

Mol Neurodegener. 2015 Sep 29;10:51. doi: 10.1186/s13024-015-0046-3. Erratum in: Mol Neurodegener. 2015;10:54.

14.

High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.

Wheeler JM, McMillan PJ, Hawk M, Iba M, Robinson L, Xu GJ, Dombroski BA, Jeong D, Dichter MA, Juul H, Loomis E, Raskind M, Leverenz JB, Trojanowski JQ, Lee VM, Schellenberg GD, Kraemer BC.

Acta Neuropathol Commun. 2015 Jun 4;3:33. doi: 10.1186/s40478-015-0210-6.

15.

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, Ghetti B, Raskind MA, Montine TJ, Bird TD, Leverenz JB, Kraemer BC.

PLoS Genet. 2014 Dec 4;10(12):e1004803. doi: 10.1371/journal.pgen.1004803. eCollection 2014 Dec.

16.

Molecular hydrogen in drinking water protects against neurodegenerative changes induced by traumatic brain injury.

Dohi K, Kraemer BC, Erickson MA, McMillan PJ, Kovac A, Flachbartova Z, Hansen KM, Shah GN, Sheibani N, Salameh T, Banks WA.

PLoS One. 2014 Sep 24;9(9):e108034. doi: 10.1371/journal.pone.0108034. eCollection 2014.

17.

Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.

Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI.

J Med Chem. 2014 Mar 27;57(6):2755-72. doi: 10.1021/jm500065f. Epub 2014 Mar 12.

18.

Blast exposure causes early and persistent aberrant phospho- and cleaved-tau expression in a murine model of mild blast-induced traumatic brain injury.

Huber BR, Meabon JS, Martin TJ, Mourad PD, Bennett R, Kraemer BC, Cernak I, Petrie EC, Emery MJ, Swenson ER, Mayer C, Mehic E, Peskind ER, Cook DG.

J Alzheimers Dis. 2013;37(2):309-23. doi: 10.3233/JAD-130182.

19.

Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS).

Korvatska O, Strand NS, Berndt JD, Strovas T, Chen DH, Leverenz JB, Kiianitsa K, Mata IF, Karakoc E, Greenup JL, Bonkowski E, Chuang J, Moon RT, Eichler EE, Nickerson DA, Zabetian CP, Kraemer BC, Bird TD, Raskind WH.

Hum Mol Genet. 2013 Aug 15;22(16):3259-68. doi: 10.1093/hmg/ddt180. Epub 2013 Apr 16.

20.

CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.

Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC.

Ann Neurol. 2013 Jul;74(1):39-52. doi: 10.1002/ana.23870. Epub 2013 Jul 8.

21.

Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.

McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC.

Biol Psychiatry. 2013 Mar 1;73(5):464-71. doi: 10.1016/j.biopsych.2012.08.027. Epub 2012 Nov 7.

22.

Potential neuroprotective strategies against tauopathy.

Wheeler JM, Guthrie CR, Kraemer BC.

Biochem Soc Trans. 2012 Aug;40(4):656-60. doi: 10.1042/BST20120017.

23.

Monoubiquitination promotes calpain cleavage of the protein phosphatase 2A (PP2A) regulatory subunit α4, altering PP2A stability and microtubule-associated protein phosphorylation.

Watkins GR, Wang N, Mazalouskas MD, Gomez RJ, Guthrie CR, Kraemer BC, Schweiger S, Spiller BW, Wadzinski BE.

J Biol Chem. 2012 Jul 13;287(29):24207-15. doi: 10.1074/jbc.M112.368613. Epub 2012 May 21.

24.

Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease.

Lim MA, Selak MA, Xiang Z, Krainc D, Neve RL, Kraemer BC, Watts JL, Kalb RG.

J Neurosci. 2012 Jan 18;32(3):1123-41. doi: 10.1523/JNEUROSCI.6554-10.2012.

25.

Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

McMillan PJ, Kraemer BC, Robinson L, Leverenz JB, Raskind M, Schellenberg G.

J Neuropathol Exp Neurol. 2011 Nov;70(11):1006-19. doi: 10.1097/NEN.0b013e31823557fb.

26.

Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis.

Wang DB, Gitcho MA, Kraemer BC, Klein RL.

Eur J Neurosci. 2011 Oct;34(8):1179-88. doi: 10.1111/j.1460-9568.2011.07803.x. Epub 2011 Jul 21. Review.

27.

MSUT2 is a determinant of susceptibility to tau neurotoxicity.

Guthrie CR, Greenup L, Leverenz JB, Kraemer BC.

Hum Mol Genet. 2011 May 15;20(10):1989-99. doi: 10.1093/hmg/ddr079. Epub 2011 Feb 25.

28.

Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.

Guthrie CR, Kraemer BC.

J Mol Neurosci. 2011 Sep;45(1):32-41. doi: 10.1007/s12031-011-9502-x. Epub 2011 Feb 22.

29.

Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy.

Liachko NF, Guthrie CR, Kraemer BC.

J Neurosci. 2010 Dec 1;30(48):16208-19. doi: 10.1523/JNEUROSCI.2911-10.2010.

30.

The role of MSUT-2 in tau neurotoxicity: a target for neuroprotection in tauopathy?

Wheeler JM, Guthrie CR, Kraemer BC.

Biochem Soc Trans. 2010 Aug;38(4):973-6. doi: 10.1042/BST0380973. Review.

31.

Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis.

Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, Schellenberg GD.

Acta Neuropathol. 2010 Apr;119(4):409-19. doi: 10.1007/s00401-010-0659-0. Epub 2010 Mar 3.

32.

SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans.

Guthrie CR, Schellenberg GD, Kraemer BC.

Hum Mol Genet. 2009 May 15;18(10):1825-38. doi: 10.1093/hmg/ddp099. Epub 2009 Mar 9.

33.

SUT-1 enables tau-induced neurotoxicity in C. elegans.

Kraemer BC, Schellenberg GD.

Hum Mol Genet. 2007 Aug 15;16(16):1959-71. Epub 2007 Jun 18.

PMID:
17576746
34.

Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans.

Kraemer BC, Burgess JK, Chen JH, Thomas JH, Schellenberg GD.

Hum Mol Genet. 2006 May 1;15(9):1483-96. Epub 2006 Apr 6.

PMID:
16600994
35.

Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9980-5. Epub 2003 Jul 18.

Supplemental Content

Loading ...
Support Center